- Home
- MKSI vs NBIX Comparison
MKSI vs NBIX Comparison
Compare MKSI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKSI | NBIX |
|---|---|---|
| Founded | 1961 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 13.9B |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MKSI | NBIX |
|---|---|---|
| Price | $244.46 | $131.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | ★ $256.00 | $175.23 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-19-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 55.52 | 41.95 |
| EPS | 4.37 | ★ 4.67 |
| Revenue | ★ $3,931,000,000.00 | $161,626,000.00 |
| Revenue This Year | $10.84 | $22.57 |
| Revenue Next Year | $8.49 | $9.56 |
| P/E Ratio | $58.56 | ★ $28.00 |
| Revenue Growth | 9.62 | ★ 977.51 |
| 52 Week Low | $54.84 | $84.23 |
| 52 Week High | $269.91 | $160.18 |
Technical Indicators
Market Signals| Indicator | MKSI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 45.37 |
| Support Level | $242.20 | $122.82 |
| Resistance Level | $246.35 | $137.37 |
| Average True Range (ATR) | 13.52 | 4.02 |
| MACD | -2.73 | 0.11 |
| Stochastic Oscillator | 31.72 | 42.87 |
Price Performance
Historical ComparisonAbout MKSI MKS Instruments Inc.
MKS Inc formerly, MKS Instruments Inc is engaged in providing instruments, subsystems, and process control systems used to measure, monitor, deliver, and control parameters of manufacturing processes. The company's product portfolio includes instruments, components, and systems required in manufacturing products such as flat panel displays, medical devices, and electronic materials, among others, used in industrial technologies, semiconductors, life and health sciences, and research and defense markets. The company organizes itself into three reportable business segments: Vacuum Solutions, Photonics Solutions, and Materials Solutions. The Vacuum Solutions segment contributes the majority of the company's revenue.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.